Chemotherapy induced myelosuppression

Area of Science:

• Oncology
• Hematology
• Clinical Pharmacology

Background:

• Chemotherapy often causes myelosuppression, particularly neutropenia, increasing infection risk.
• Effective management of chemotherapy-induced neutropenia is crucial for patient outcomes.

Observation:

• A retrospective analysis of 202 solid tumour and lymphoma patients revealed high rates of World Health Organisation (WHO) grade 3 (26.1%) and grade 4 (25.7%) neutropenia.
• Fever complicated 23.1% of neutropenic episodes, leading to hospitalization in 28 patients and a 21.4% mortality rate among those with infections.
• Prophylactic Granulocyte-Colony Stimulating Factors (G-CSF) were used in 18.4% of treatments, with 33 patients receiving them.

Findings:

• Neutropenia severity peaked around the first and sixth chemotherapy courses.
• Median neutrophil recovery time was 3 days (mean 4.6 days).
• Prophylactic G-CSF use may have reduced severe neutropenia, and its use in existing neutropenia might have shortened duration and severity, though mortality for febrile neutropenia remained high.

Implications:

• Findings suggest G-CSF can mitigate neutropenia but does not eliminate the risk of severe outcomes or mortality from febrile neutropenia.
• Further research into optimizing G-CSF use and alternative strategies is warranted to improve patient survival and treatment tolerance.
• This study highlights the persistent challenge of managing severe neutropenia in oncology patients.